文献速递淋巴瘤

固定疗程维奈克拉-奥妥珠单抗治疗初治CLL的生活质量:CLL14随机3期试验结果

Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.
PubMed 文献 · Am J Hematol · 2021-06-22

CLL14试验比较固定疗程维奈克拉-奥妥珠单抗(Ven-Obi)与苯丁酸氮芥-奥妥珠单抗(Clb-Obi)在初治CLL患者中的疗效与生活质量。患者报告结局显示,Ven-Obi组总体健康状况/生活质量在治疗第3周期即出现至少8分的临床意义改善,而Clb-Obi组延迟至第8周期;两组躯体功能和角色功能维持基线水平,CLL症状及症状干扰低且组间可比。

要点

  • Ven-Obi治疗初治CLL不损害生活质量,且较Clb-Obi更早改善总体健康状况/生活质量。
  • 两组躯体功能和角色功能在整个治疗及随访期间维持基线水平,无相关改善或恶化。
  • CLL症状、核心癌症症状及症状干扰在基线和治疗随访期间均较低且组间可比。

核心结论

  • Ven-Obi较高疗效未伴随生活质量损害,并在老年不适合患者中实现CLL相关症状的早期缓解。

研究设计与样本

  • 随机3期CLL14试验,评估固定疗程Ven-Obi对比Clb-Obi在初治CLL患者中的患者报告结局。
  • 采用MDASI核心量表及CLL模块和EORTC QLQ-C30评估生活质量。

主要发现

  • EORTC QLQ-C30显示,Ven-Obi组总体健康状况/生活质量在治疗第3周期平均改善至少8分,Clb-Obi组延迟至第8周期。
  • 躯体功能(Clb-Obi均值75.9±20.1,Ven-Obi 76.9±19.4)、角色功能(73.6±27.86和72.6±26.9)及总体健康状况/生活质量(63.6±21.0和60.3±20.5)基线组间可比,治疗随访期间维持。
  • MDASI显示基线CLL症状(1.5±1.2和1.6±1.3)、核心癌症症状(1.5±1.4和1.8±1.7)及症状干扰(2.1±2.3和2.3±2.3)低且组间可比,治疗随访期间维持。

临床怎么用

  • 对于初治CLL老年不适合患者,Ven-Obi在提高疗效的同时不损害生活质量,并可早期缓解CLL相关症状。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic lymphocytic leukemia (CLL)-related symptoms impair the well-being of patients, making improvement of health-related quality of life (QoL) a goal of treatment. The CLL14 trial demonstrated higher efficacy of fixed-duration venetoclax-obinutuzumab (Ven-Obi) compared to chlorambucil-obinutuzumab (Clb-Obi) in patients with previously untreated CLL. To assess patients' QoL, the following patient-reported outcomes (PRO) measures were assessed: the M.D. Anderson Symptom Inventory (MDASI) core instrument and CLL module and the EORTC Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). At treatment start, physical functioning (mean 75.9 [standard deviation (SD) ± 20.1] in the Clb-Obi arm and 76.9 [±19.4] in the Ven-Obi arm), role functioning (73.6 [±27.86] and 72.6 [±26.9]) and GHS/QoL (63.6 [±21.0] and 60.3 [±20.5]) were comparable between treatment arms per EORTC QLQ-C30 scale scores. Baseline levels of physical and role functioning were maintained throughout treatment and follow-up, with no relevant improvement or deterioration. On average, patients treated with Ven-Obi showed a meaningful improvement of GHS/QoL during treatment and follow-up by at least eight points at cycle three, whereas improvement was delayed until cycle eight with Clb-Obi. According to MDASI scores, CLL symptoms (1.5 [±1.2] and 1.6 [±1.3]), core cancer symptoms (1.5 [±1.4] and 1.8 [±1.7]) and symptom interference (2.1 [±2.3] and 2.3 [±2.3]) were generally low and comparable between treatment arms at baseline and were maintained throughout treatment and follow-up. This analysis demonstrates that the higher efficacy of Ven-Obi is not associated with QoL impairment and that Ven-Obi achieves early relief of CLL-related symptoms in elderly unfit patients.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Al-Sawaf O, Gentile B, Devine J, et al. Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial. Am J Hematol. 2021. PMID: 34050972. doi:10.1002/ajh.26260

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。